Type 2 Diabetes Damages the Pancreas, Or Does It?

For years, researchers have reported abnormalities involving the exocrine pancreas in people with type 2 diabetes. That has raised an important clinical question: does type 2 diabetes routinely damage the digestive side of the pancreas, or are the two conditions simply associated in some patients? New prospective research examining exocrine pancreatic function in people with type 2 diabetes suggests the relationship may be less straightforward than previously thought.

In a carefully selected group, researchers found no clinically meaningful exocrine pancreatic phenotype associated with type 2 diabetes. The findings could help clinicians decide when gastrointestinal symptoms deserve pancreatic testing rather than assuming pancreatic dysfunction is simply part of diabetes.

Table of Contents

• Endocrine versus exocrine pancreatic function
• What the new study found
• Why earlier studies reached different conclusions
• What the findings could mean for clinical practice
• Conclusion
• Frequently asked questions

How Endocrine and Exocrine Pancreatic Function Differ

The pancreas performs two major jobs, and separating them is essential when interpreting this research. Its endocrine cells release hormones such as insulin and glucagon into the bloodstream. Type 2 diabetes primarily involves this endocrine system through insulin resistance and progressive beta-cell dysfunction.

The exocrine pancreas has a different role. It produces digestive enzymes that help the small intestine break down carbohydrates, proteins, and fats. When enzyme production or delivery becomes inadequate, patients may develop exocrine pancreatic insufficiency, or EPI.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, EPI can cause diarrhea, bloating, abdominal discomfort, greasy stools, weight loss, and nutritional problems. Diabetes is recognized as one condition associated with EPI, although pancreatic enzyme problems also occur with diseases such as chronic pancreatitis.

Importantly, diabetes caused by underlying exocrine pancreatic disease is distinct from typical type 2 diabetes. This condition is often called type 3c or pancreatogenic diabetes. DiabetesInControl has also reviewed the diagnostic clues in When "Type 2" Isn't Type 2: Clues to Type 3c Diabetes.

New Study Challenges the Link Between Type 2 Diabetes and Exocrine Pancreatic Dysfunction

The new prospective, assessor-blinded case-control study, published in Diabetes Research and Clinical Practice, examined whether adults with type 2 diabetes actually have a clinically meaningful exocrine pancreatic phenotype.

Researchers studied 57 adults with type 2 diabetes and 53 controls. Participants were undergoing endoscopic ultrasound for reasons unrelated to pancreatic disease, and people with known or suspected pancreatic disease were excluded. Controls were frequency-matched for age and sex.

Rather than relying on a single marker, investigators used several measures. These included endoscopic ultrasound abnormalities, pancreatic body diameter, elastography, fecal elastase-1, gastrointestinal symptoms, quality-of-life measures, and nutritional markers. Importantly, the endosonographers were blinded to diabetes status.

The results were notable. Overall ultrasound abnormalities were not significantly different between groups. Pancreatic body diameter, elastography measurements, fecal elastase-1 levels, nutritional markers, and pancreatic insufficiency-related quality-of-life measures were also comparable.

Low fecal elastase-1 below 200 µg/g occurred in 10.9% of participants with type 2 diabetes versus 18.0% of controls. Therefore, low elastase was not more common in the diabetes group. However, early satiety and diarrhea were reported more often among participants with type 2 diabetes.

The authors concluded that, within this selected population, type 2 diabetes was not associated with clinically relevant exocrine dysfunction, pancreatic atrophy, or a consistent chronic pancreatitis-like ultrasound phenotype.

Why Previous Pancreatic Research Still Matters

These findings do not mean the exocrine pancreas is unaffected in every person with type 2 diabetes. Instead, they highlight the difference between detecting biological or structural abnormalities and demonstrating clinically significant exocrine disease.

Earlier research has found structural differences in pancreatic tissue from people with diabetes. For example, research examining human donor pancreata has reported findings such as acinar-to-ductal metaplasia, lobular fibrosis, and angiopathy in people with type 2 diabetes compared with matched donors without diabetes.

Other research has also reported lower fecal elastase levels or pancreatic abnormalities in some populations with diabetes. However, differences in patient selection, diabetes duration, obesity, age, testing methods, and underlying pancreatic disease can influence results.

The new study addresses the question from another angle. Instead of asking whether any pancreatic abnormality could be detected, researchers examined whether these differences formed a consistent, clinically relevant exocrine pancreatic phenotype in people with type 2 diabetes. In their selected population, they did not.

Still, the study was relatively small and involved patients already referred for endoscopic ultrasound. People with known or suspected pancreatic disease were excluded. Consequently, its results should not be generalized to every person with type 2 diabetes.

Gastrointestinal Symptoms May Still Justify Targeted Testing

The practical message is not to ignore pancreatic symptoms. Rather, the findings support a phenotype-based approach instead of routine pancreatic testing solely because a patient has type 2 diabetes.

Persistent diarrhea, steatorrhea, unexplained weight loss, bloating, nutritional deficiencies, or other signs of malabsorption can justify further evaluation. A history of pancreatitis, pancreatic surgery, pancreatic cancer, or another pancreatic disorder may increase suspicion further.

The American Gastroenterological Association recommends considering EPI in people with longstanding diabetes when appropriate clinical features are present. Fecal elastase is generally used as an initial test. Levels below 100 µg/g provide stronger evidence of EPI, while results between 100 and 200 µg/g are considered indeterminate.

Clinicians should also remember that gastrointestinal symptoms in diabetes have many possible explanations. Medication effects, gastroparesis, celiac disease, infections, and other gastrointestinal disorders can overlap with symptoms associated with EPI.

Therefore, pancreatic testing should answer a clinical question rather than simply confirm that a patient has diabetes. When symptoms suggest pancreatic disease or another gastrointestinal condition, patients should discuss appropriate evaluation with a qualified healthcare professional.

Conclusion

The relationship between the exocrine pancreas and type 2 diabetes is more nuanced than a simple cause-and-effect model. Although earlier studies have identified structural and functional pancreatic differences in some people with diabetes, this prospective study found no clinically relevant exocrine pancreatic phenotype in its selected type 2 diabetes population.

For clinicians, the findings support targeted assessment. Type 2 diabetes alone may not justify routine testing for exocrine dysfunction. However, unexplained gastrointestinal symptoms, weight loss, malabsorption, nutritional deficiencies, or a history suggesting pancreatic disease should still prompt closer evaluation.

Frequently Asked Questions

What is the difference between the endocrine and exocrine pancreas?

The endocrine pancreas produces hormones such as insulin and glucagon that help regulate blood glucose. The exocrine pancreas produces digestive enzymes that help the body break down food.

Does type 2 diabetes cause exocrine pancreatic insufficiency?

Diabetes can be associated with EPI, but the new study suggests clinically relevant exocrine dysfunction is not necessarily a routine feature of type 2 diabetes. Individual symptoms, medical history, and other risk factors remain important.

What symptoms may suggest exocrine pancreatic insufficiency?

Possible symptoms include diarrhea, greasy or foul-smelling stools, bloating, excessive gas, abdominal discomfort, unexplained weight loss, and signs of nutrient deficiency. However, these symptoms can have many other causes.

How is exocrine pancreatic insufficiency tested?

Fecal elastase-1 is commonly used as an initial test. Additional blood tests, imaging, or pancreatic function testing may be appropriate depending on the patient's symptoms and clinical history.

What is type 3c diabetes?

Type 3c, or pancreatogenic diabetes, develops because of disease or damage involving the exocrine pancreas. Chronic pancreatitis, pancreatic surgery, and other pancreatic disorders can cause it, making accurate classification important for treatment.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.